hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and

Clinical trials are essential processes in the field of medicine, helping to determine the safety and effectiveness of new treatments, drugs, or medical procedures. These trials involve volunteers who agree to participate

Despite scientific progress made in the last decades, nearly 1 billion of individuals are affected by tropical diseases yearly, according to the World Health Organization. The development of new vaccines

Canary Wharf is set to receive a multi-million-pound cash injection to build more homes in the capital’s banking district. As part of the Spring Budget, Chancellor Jeremy Hunt announced he would pour

It’s no secret that women across a spectrum of industries often face challenges when trying to get ahead and make their mark in the business marketplace. The business development field

hVIVO plc (LON:HVO), a name not often headlined among the largest market cap companies, has recently led the AIM gainers, catching the eye of shareholders and investors alike. This surge

Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial

A leading firm testing infectious diseases, hVIVO, has reported a record year as it looks to start work on an £80m orderbook in 2024. The London-listed firm said it achieved

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and

Healthcare company hVIVO, formerly Open Orphan, said today it expects to report full year revenues of £56m for 2023, a 15.5% increase on the £48.5m reported in 2022. The company